Evidence map›Paper›PMID 40468224›Full record

ArticleBMC gastroenterology2025

The potential value of serum pepsinogen and gastrin-17 for the diagnosis of chronic atrophic gastritis at different stages of severity: a clinical diagnostic study.

Tianyi Zhang, Xuyun Zhou, Xiangxiang Meng, Jianxin Li, Sujun Hou, Junmei Wang, Mengmeng Yin, Long Cao, Baitian Wang

Abstract read
In one paragraph

Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Pepsinogen Assay Findings in Individuals With Gastric Atrophy and Intestinal Metaplasia.The Korean journal of helicobacter and upper gastrointestinal research · 2026
    Review
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tianyi ZhangDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Xuyun ZhouDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Xiangxiang MengDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Jianxin LiDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Sujun HouDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Junmei WangDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Mengmeng YinDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Long CaoDepartment of Acupuncture and Moxibustion, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China.
Baitian WangDepartment of Clinical Laboratory, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, 276800, China. 13792001467@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPepsinogen (PG) and gastrin-17 (G-17) are crucial in the gastric digestive processes. This study aimed to assess the diagnostic value of the serum PG and G-17 in identifying chronic atrophic gastritis (CAG) at different stages of severity under varying Helicobacter pylori (H. pylori) infection statuses.

methodsWe enrolled 300 participants from August 2023 to May 2024. All participants underwent gastroscopy with biopsy, and blood samples were taken for pepsinogen I (PGI), pepsinogen II (PGII), G-17, and H. pylori tests. The differences in G-17 and PG-related parameters were analyzed across groups, taking H. pylori infection status into account. The diagnostic performance of these markers was then evaluated both individually and in combination to distinguish CAG stages of severity. Statistical analysis was performed using SPSS statistical software.

resultsAccording to pathological results, patients were divided into the non-atrophic gastritis group (NAG, n = 179), the mild atrophic gastritis group (MAG, n = 62), and the moderate and severe atrophic gastritis group (MSAG, n = 59). In the same pathological groups (NAG, MAG, and MSAG), PGII levels were higher in the H. pylori-positive subgroup, while the PGI/PGII ratio (PGR) was lower (p < 0.05). Serum PGII and G-17 levels increased with the pathological severity of the mucosa (p < 0.001, r = 0.364 and p < 0.001, r = 0.304, respectively), while PGR levels decreased with mucosal deterioration (p < 0.001, r = -0.407). Combination of PGI, PGII, PGR, and G-17 showed an area under the curve (AUC) of 0.723 (95% CI: 0.662-0.784), with a sensitivity of 65.29% and a specificity of 73.18% for detecting the presence of any CAG. For progressive CAG, which was defined by MSAG and classified into stages II-IV according to the Operative Link on Gastritis Assessment (OLGA) system, the AUC was 0.759 (95% CI: 0.683-0.836), with a sensitivity of 66.10% and a specificity of 83.40%, demonstrating the potential for even higher diagnostic ability. Among all the H. pylori-positive cohorts, PGII exhibited a higher AUC compared to the combined diagnostic approach using PGI, PGII, PGR, and G-17 (CAG: 0.656 vs. 0.654, MAG: 0.589 vs. 0.571, MSAG: 0.707 vs. 0.706, respectively).

conclusionSerum PG and G-17 show potential in identifying CAG and MSAG. However, their diagnostic accuracy for MAG remains limited and would be better used as adjunctive indicators in conjunction with endoscopic examination. Further validation in larger, multi-center studies is needed to assess their utility in clinical practice.

Indexed as

GastrinsGastritis, AtrophicHelicobacter InfectionsPepsinogen AAdultAgedBiomarkersChronic DiseaseFemaleGastric MucosaGastroscopyHelicobacter pyloriHumansMaleMiddle AgedPepsinogen CBiomarkersgastrin 17GastrinsPepsinogen APepsinogen CChronic atrophic gastritisGastrin-17H. pyloriPepsinogenSeverity

Identifiers

PMID40468224
PMCPMC12135244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.